Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$159.80M
EBITDA Margin
4.91%
TTM Avg
4.91%
3Y Avg
4.91%
5Y Avg
4.91%
Market Cap
$159.22M
EBITDA Margin
-0.19%
TTM Avg
-1.66%
3Y Avg
-11.02%
5Y Avg
-42.72%
Market Cap
$159.14M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$162.04M
EBITDA Margin
-65.55%
TTM Avg
-49.11%
3Y Avg
-55.76%
5Y Avg
-50.22%
Market Cap
$165.27M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
Market Cap
$165.32M
EBITDA Margin
14.98%
TTM Avg
2.40%
3Y Avg
-11.30%
5Y Avg
-6.96%
Market Cap
$153.79M
EBITDA Margin
-18.75%
TTM Avg
-31.07%
3Y Avg
-38.37%
5Y Avg
-40.79%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | $159.78M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | 4.91% | 4.91% | 4.91% | 4.91% |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | -0.19% | -1.66% | -11.02% | -42.72% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -416.41% | -228.13% | -163.44% | -116.60% |
| Quanterix Corporation (QTRX)vs › | $162.04M | -65.55% | -49.11% | -55.76% | -50.22% |
| Inogen, Inc. (INGN)vs › | $156.22M | -2.74% | -4.58% | -13.60% | -7.28% |
| Nkarta, Inc. (NKTX)vs › | $165.27M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 14.98% | 2.40% | -11.30% | -6.96% |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -18.75% | -31.07% | -38.37% | -40.79% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
